The Fishing Harpoon is a Polearm in The Legend of Zelda: Tears of the Kingdom. This item was meant for fishing, but its spearhead is sharp enough that it can be used as a weapon in a pinch. "A ...

"Harpoon with a tip made from a sharpened meteorite shard. Wielded by the claymen who infest dynastic remains. The blade emits a faint light and deals magic damage." The Clayman's Harpoon Default ...

RCUS is now resetting its strategy after its Phase 3 STAR-221 was discontinued. This removes domvanalimab for upper-GI cancers as a key catalyst. Instead, they’ll focus now on Casdatifan (AB521), ...

Edwards Lifesciences Corp. has resolved a court case seeking up to $140 million over claims it failed to commercialize a heart valve device it gained in its acquisition of Harpoon Medical Inc. The ...

Dec 12 (Reuters) - Arcus Biosciences (RCUS.N), opens new tab said on Friday it would stop a late-stage study testing its experimental cancer drug combination in patients with advanced stomach and ...

Arcus Biosciences and Gilead Sciences are discontinuing a Phase 3 trial of an experimental cancer treatment after an interim review showed the therapy was unlikely to help patients live longer. Arcus ...

Arcus Biosciences (RCUS) fell ~14% in the premarket on Friday after the company announced the discontinuation of a Phase 3 trial designed to evaluate its anti-TIGIT therapy domvanalimab in gastric and ...

A key late-stage trial of Arcus Biosciences and Gilead Sciences' anti-TIGIT antibody domvanalimab has flopped, leading Arcus to refocus its R&D priorities and abandon several studies of the drug. The ...

Arcus Biosciences said it will discontinue a late-stage trial for its potential cancer treatment due to futility. The study, which was being conducted in partnership with Gilead Sciences, aimed to ...

The Phase 3 STAR-221 study evaluating a domvanalimab-based combination in upper gastrointestinal cancers will be discontinued due to futility Arcus is continuing to expand its development program for ...

The loss of domvanalimab is the latest in a string of high-profile failures recorded across the biopharma world for the TIGIT modality, including from GSK, Merck and Roche. The TIGIT class has ...

A study using TIGIT and PD-1 drugs for gastrointestinal disease was canceled for “futility” at an early checkpoint, another blow to research on a once-promising target. Arcus executives said trial ...